Stocks
Allogene Therapeutics (ALLO) EBITDA margin US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -148.8% | -205 924% | -329 543% | -1 106 032% | ||||
| Changes by years, y/y, % | -205 775pp | -123 619pp | -776 489pp | +1 851.7% | |||||
Allogene Therapeutics. EBITDA margin, %
Allogene Therapeutics. EBITDA margin, changes, pp
Allogene Therapeutics (ALLO) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA margin, % | ? | -318 617% | -349 532% | -266 886% | -155 573% | -279 295% | ||
| Changes by years, y/y, % | -193 535pp | -264 742pp | -106 419pp | +42 951pp | +39 321pp | |||
| Changes by quarters, q/q, % | -120 093pp | -30 915pp | +82 645pp | +111 314pp | -123 723pp | |||
